
|Articles|September 18, 2015
Sara M. Tolaney on Neoadjuvant Treatment Considerations for Triple-Negative Breast Cancer
Author(s)Sara M. Tolaney, MD, MPH
There are many clinical trial opportunities, Tolaney says, before surgery.
Advertisement
Sara M. Tolaney, medical oncologist, Dana-Farber Cancer Institute, discusses neoadjuvant treatment considerations for patients with triple-negative breast cancer.
“[There are] lots of potential clinical trial opportunities prior to surgery because we do have this question about whether or not platinum therapy is beneficial,” Tolaney says.
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Navigating Life’s Path With Multiple Myeloma
2
What the Art of Kintsugi Can Teach During a Cancer Journey
3
FDA Fast Tracks NG-350A for Some With Advanced Rectal Cancer
4
Questions of Faith and Spirituality Matter for Patients with Gynecologic Cancers
5